Abstract

You have accessJournal of UrologyCME1 May 2022PD18-05 CLINICAL CHARACTERISTICS AND RISK FACTORS FOR SURVIVAL IN AFFECTED OFFSPRING OF VON HIPPEL-LINDAU DISEASE PATIENTS Kenan Zhang, Cai Lin, Wuping Yang, Kan Gong, and Yawei Xu Kenan ZhangKenan Zhang More articles by this author , Cai LinCai Lin More articles by this author , Wuping YangWuping Yang More articles by this author , Kan GongKan Gong More articles by this author , and Yawei XuYawei Xu More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000002556.05AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Von Hippel-Lindau (VHL) disease is an autosomal dominant genetic tumor syndrome with poor prognosis. The clinical manifestation was found to be more serious in affected offspring of VHL patients, but the risk factors and survival for them has never been reported before. We aimed to explore how these patients were influenced by genetic and clinical factors. METHODS: In this retrospective study, we collected 372 affected offspring of VHL patients from 118 unrelated VHL families. Patients were stratified into different groups based on sets of variables. The age-related risk, overall survival and central nervous system haemangioblastoma (CHB)-specific survival were analyzed between different groups using Kaplan-Meier survival analysis and Cox regression analysis. RESULTS: The estimated median life expectancy and median onset age for affected offspring of VHL patients was 66 years and 28 years respectively. The later generation and patients with mutations in exon 3 had an earlier onset age. The first presenting symptom was the only independent risk factor influencing overall survival and CHB-specific survival. Patients that the first presenting symptom is CNS significantly had a lower life expectancy both in overall survival and CHB-specific survival analysis. CONCLUSIONS: This study indicated that affected offspring of VHL patients with CNS as the first presenting symptom was an independent risk factor for overall survival and CHB-specific survival, which is helpful to clinical decision-making and generate a more precise surveillance protocol. Source of Funding: This study was granted by the ethical committee of Peking University First Hospital (2021KY336, Beijing, China). Each participant provided signed informed consent before participate in the present study and all patients understood the process and possible consequences © 2022 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 207Issue Supplement 5May 2022Page: e344 Advertisement Copyright & Permissions© 2022 by American Urological Association Education and Research, Inc.MetricsAuthor Information Kenan Zhang More articles by this author Cai Lin More articles by this author Wuping Yang More articles by this author Kan Gong More articles by this author Yawei Xu More articles by this author Expand All Advertisement PDF DownloadLoading ...

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call